Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study

American Journal of Clinical Nutrition

Volumn 99, Issue 3, 2014, Pages 535-542

  Eslamparast, Tannaz ^a,b   Poustchi, Hossein ^b   Zamani, Farhad ^c   Sharafkhah, Maryam ^b   Malekzadeh, Reza ^b   Hekmatdoost, Azita ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PLACEBO; SYNBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; CALORIC INTAKE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; ELASTOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LIFESTYLE MODIFICATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS; TREATMENT DURATION;

ADULT; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; DIET, REDUCING; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; INTENTION TO TREAT ANALYSIS; LIFE STYLE; LIVER CIRRHOSIS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; MOTOR ACTIVITY; OVERWEIGHT; PATIENT DROPOUTS; PATIENT EDUCATION AS TOPIC; PILOT PROJECTS; SYNBIOTICS;

EID: 84896818656     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.113.068890     Document Type: Article

References (31)

1. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132-8. (Pubitemid 40038911)
2. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands J, Fava J, Wing R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
3. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008:28:26-42. (Pubitemid 351326531)
4. Yang L, Seki E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol 2012:3:138.
5. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases.World J Gastroenterol 2010;16:403-10.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
7. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, Nardone G. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012;22:471-6.
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9. (Pubitemid 29258890)
9. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Masciana R, Forgione A, Gabrieli ML, Perotti G. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87.
10. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 2006;44(2):253-61. (Pubitemid 43071224)
11. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(S1):S99-S112.
12. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. J Gastroenterol 2006;131(3):934-45. (Pubitemid 44307061)
13. Rijkers GT, de Vos WM, Brummer R-J, Morelli L, Corthier G, Marteau P. Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr 2011;106(09):1291-6.
14. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009;49(3):989-97.
15. Nardone G, Compare D, Liguori E, Di Mauro V, Rocca A, Barone M, Napoli A, Lapi D, Iovene MR, Colantuoni A. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol 2010;299(3):G669-G76.
16. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37(2):343-50. (Pubitemid 36152533)
17. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008;49(5):821-30.
18. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005;39(6):540-3. (Pubitemid 40863651)
19. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, etal. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive diseases and sciences 2011:1-9.
20. National Heart, Lung, and Blood Institute. The Practical Guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity, 2000.
21. Organization WH. STEPwise approach to surveillance (STEPS). Geneva, Switzerland: World Health Organization, 2012.
22. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9. (Pubitemid 15018832)
23. Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran, Iran: Nashre Olume Keshavarzy 1999.
24. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DR, Schmitz KH, Emplaincourt PO. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32(suppl):498-504.
25. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011;22(8):699-711.
26. dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB Activation, Rather Than TNF, Mediates Hepatic Inflammation in a Murine Dietary Model of Steatohepatitis. Gastroenterology 2005;129(5):1663-74. (Pubitemid 41597405)
27. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007;23:62-8. (Pubitemid 44959762)
28. Creely SJ, McTernan PG, Kusminski CM, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E740-7. (Pubitemid 46411051)
29. Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, Da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009;8:20.
30. Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon 2011;11:157-8.
31. Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol 2012;11:172-8.